Your browser doesn't support javascript.
loading
Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
Hawkins, Eric J; Malte, Carol A; Hagedorn, Hildi J; Gordon, Adam J; Williams, Emily C; Trim, Ryan S; Blanchard, Brittany E; Lott, Aline; Danner, Anissa N; Saxon, Andrew J.
Afiliación
  • Hawkins EJ; From the Health Services Research & Development (HSR&D) Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, Seattle, WA (EJH, CAM, ECW, AL, AND, AJS); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, WA (EJH, CAM, HJH, AL, AND, AJS); HSR&D Center for Care Delivery & Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN (HJH); H
J Addict Med ; 18(3): 240-247, 2024.
Article en En | MEDLINE | ID: mdl-38329814
ABSTRACT

OBJECTIVES:

Buprenorphine, a medication for opioid use disorder (OUD), is underutilized in general medical settings. Further, it is inequitably received by racialized groups and persons with comorbidities. The Veterans Health Administration launched an initiative to increase buprenorphine receipt in primary care. The project's objective was to identify patient-related factors associated with buprenorphine receipt and retention in primary care clinics (n = 18) participating in the initiative.

METHODS:

Retrospective cohort quality improvement evaluation of patients 18 years or older with 2 or more primary care visits in a 1-year period and an OUD diagnosis in the year before the first primary care visit (index date). Buprenorphine receipt was the proportion of patients with OUD who received 1 or more buprenorphine prescriptions from primary care providers during the post-index year and retention the proportion who received buprenorphine for 180 days or longer.

RESULTS:

Of 2880 patients with OUD seen in primary care, 11.7% (95% confidence interval [CI], 10.6%-12.9%) received buprenorphine in primary care, 58.2% (95% CI, 52.8%-63.3%) of whom were retained on buprenorphine for 180 days or longer. Patients with alcohol use disorder (adjusted odds ratio [AOR], 0.39; 95% CI, 0.27-0.57), nonopioid drug use disorder (AOR, 0.64; 95% CI, 0.45-0.93), and serious mental illness (AOR, 0.60; 95% CI, 0.37-0.97) had lower buprenorphine receipt. Those with an anxiety disorder had higher buprenorphine receipt (AOR, 1.42; 95% CI, 1.04-1.95). Buprenorphine receipt (AOR, 0.55; 95% CI, 0.35-0.87) and 180-day retention (AOR, 0.40; 95% CI, 0.19-0.84) were less likely among non-Hispanic Black patients.

CONCLUSIONS:

Further integration of addiction services in primary care may be needed to enhance buprenorphine receipt for patients with comorbid substance use disorders, and interventions are needed to address disparities in receipt and retention among non-Hispanic Black patients.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Atención Primaria de Salud / Buprenorfina / Tratamiento de Sustitución de Opiáceos / Accesibilidad a los Servicios de Salud / Trastornos Relacionados con Opioides Tipo de estudio: Prognostic_studies País/Región como asunto: America do norte Idioma: En Revista: J Addict Med Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Atención Primaria de Salud / Buprenorfina / Tratamiento de Sustitución de Opiáceos / Accesibilidad a los Servicios de Salud / Trastornos Relacionados con Opioides Tipo de estudio: Prognostic_studies País/Región como asunto: America do norte Idioma: En Revista: J Addict Med Año: 2024 Tipo del documento: Article